

NAME: DATE: TOTAL SCORE: 

# Scores to Assess Atopic Dermatitis

## EASI Eczema Area and Severity Index


EASI is a scoring system used to measure the extent (area) and severity of atopic dermatitis. The body is divided into four regions. Each region is scored separately for area and severity of atopic dermatitis to determine a final EASI score.<sup>1,2</sup>

HEAD & NECK	UPPER EXTREMITIES	TRUNK (INCLUDING THE GENITAL AREA)	LOWER EXTREMITIES (INCLUDING THE BUTTOCKS)
-------------	-------------------	------------------------------------	--

## HOW TO DETERMINE AN EASI SCORE

### STEP 1: AREA

Determine the extent (area) of atopic dermatitis affecting your patient. Score each of the four body regions from 0 to 100%. Use the percentages in the illustrations below to guide your estimates for each body region.<sup>1</sup>



Adapted from HOME (Harmonising Outcome Measures for Eczema) EASI User Guide 2016<sup>1</sup>

Then, using the table below, give each respective body region a score between 0 and 6 based on the estimated percentage involvement.<sup>1</sup>

% INVOLVEMENT	0	1-9%	10-29%	30-49%	50-69%	70-89%	90-100%
SCORE	0	1	2	3	4	5	6

DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

DUPIXENT can be used with or without topical corticosteroids.

**DUPIXENT**<sup>®</sup>  
(dupilumab) Injection

## STEP 2: SEVERITY

















Determine the severity of atopic dermatitis in each of the four body regions. Severity is graded across four dimensions, called signs:

ERYTHEMA	EDEMA/PAPULATION	EXCORIATION	LICHENIFICATION
----------	------------------	-------------	-----------------

Each sign must be assigned a number ranging from 0 (none), 1 (mild), 2 (moderate), to 3 (severe) for each of the four body regions. Use the severity atlas below to guide your estimates.<sup>1</sup>

- Take an average of the severity across the involved region.
- Half points (1.5 and 2.5) may be used. 0.5 is not permitted – if a sign is present it should be at least mild (1).
- Palpation may be useful in assessing edema/papulation as well as lichenification.

### EASI lesion severity atlas

	NONE = 0	MILD = 1	MODERATE = 2	SEVERE = 3
<b>Erythema</b>		 Faintly detectable, pink	 Clearly distinguishable dull red	 Deep dark or fiery bright red
<b>Edema/ papulation</b>		 Barely perceptible elevation	 Clearly perceptible elevation but not prominent	 Prominent elevation
<b>Excoriation</b>		 Scant, superficial excoriation	 Many superficial and/or some deep excoriations	 Extensive superficial and/or many deep excoriations
<b>Lichenification</b>		 Slight skin thickening; markings minimally exaggerated	 Thickened skin with exaggerated markings and/or some prurigo nodules	 Prominent thickening; exaggerated markings creating deep furrows and/or many prurigo nodules

## STEP 3: CALCULATE

Record your estimates of area and severity then calculate the final EASI score.<sup>1</sup>

- Record the intensity of each of the four signs (from Step 2). Calculate the severity score by adding scores for the four signs. Do this for each body region.
- Record the area score for each body region (from Step 1).
- Multiply the severity score by the area score and by the multiplier. The multiplier is different for each body region. The multipliers in this table are for adults.
- Add the total scores for each body region to determine the final EASI score.

BODY REGION	ERYTHEMA (0-3)	EDEMA/PAPULATION (0-3)	EXCORIATION (0-3)	LICHENIFICATION (0-3)	SEVERITY SCORE	AREA SCORE (0-6)	MULTIPLIER	SCORE PER BODY REGION
Head & neck		+	+	+	=	x	x 0.1	
Trunk		+	+	+	=	x	x 0.3	
Upper extremities		+	+	+	=	x	x 0.2	
Lower extremities		+	+	+	=	x	x 0.4	
The final EASI score is the sum of the 4 scores per body region:								_____ (0-72)
Family name: _____ Given name: _____								
Date of birth (YYYY/MM/DD): _____ / _____ / _____ Date (YYYY/MM/DD): _____ / _____ / _____								

Adapted from HOME (Harmonising Outcome Measures for Eczema) EASI User Guide 2016<sup>1</sup>

## STEP 4: INTERPRETATION

A suggested interpretation of the EASI score adapted from Leshem *et al.* 2015:<sup>3†</sup>

<b>CLEAR</b>	0
<b>ALMOST CLEAR</b>	0.1-1.0
<b>MILD</b>	1.1-7.0
<b>MODERATE</b>	7.1-21.0
<b>SEVERE</b>	21.1-50.0
<b>VERY SEVERE</b>	50.1-72.0

In the DUPIXENT clinical trials, moderate-to-severe atopic dermatitis was defined by an Eczema Area and Severity Index (EASI) score  $\geq 16$  on a scale of 0 to 72.<sup>4</sup>

Please consult the Product Monograph at <http://products.sanofi.ca/en/dupixent-en.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-589-6215.

† Retrospective study of pediatric and adult patients with AD that assessed interpretability of the EASI scale. Interpretability was evaluated by stratifying the EASI scores according to the Investigator Global Assessment (IGA). Only patients who had documentation of both the Investigator Global Assessment (IGA) and EASI scores at the same encounter were included. A total of 170 AD patients were included in the study.

**References:** 1. EASI User Guide, HOME - Harmonising Outcome Measures for Eczema website. <http://www.homeforeczema.org/documents/easi-user-guide-dec-2016-v2.pdf>. Accessed May 11, 2018. 2. Hanifin JM, *et al.* The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. *Exp Dermatol.* 2001;10:11-18. 3. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. *Br J Dermatol.* 2015;172(5):1353-1357. 4. Dupixent® Product Monograph, sanofi-aventis Canada Inc., March 25, 2022.

DUPIXENT® and Sanofi logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.

REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.

© 2022 sanofi-aventis Canada Inc. All rights reserved.